Conference Coverage
Conference Coverage
Do black patients with type 2 diabetes gain cardiac benefit from the SGLT2 and GLP-1 drugs?
SAN FRANCISCO - New findings suggest there is no effect on cardiovascular outcomes, although the analysis has limitations
Conference Coverage
Aggressive lowering of LDL cholesterol: Is it a good idea?
SAN FRANCISCO –
Conference Coverage
Three out of five ain’t bad? Some diabetes measures improved over 17 years
SAN FRANCISCO – It might be time for team care of patients with diabetes, an epidemiologist says.
Conference Coverage
Which antidiabetic for elderly patients? It depends on their CV risk
Balancing heart failure with cardiovascular events
Conference Coverage
CGMs on the rise: New goals set time in range
The targets “should be considered an integral component of CGM data analysis and day-to-day treatment decision making.”
Conference Coverage
Breast cancer linked to 23% higher risk for new diabetes
It’s a “clear signal” of extra risk, researcher says, but there’s no explanation yet.
Conference Coverage
Drastic weight loss prevents progression to type 2 diabetes, PREVIEW data suggest
SAN FRANCISCO – In patients with prediabetes, weight loss of 8% or more over 2 months reduced conversion to diabetes over 3 years.
Conference Coverage
GLP-1 RA dulaglutide yields cardiac gains, even in non–at-risk patients
SAN FRANCISCO – REWIND data show that over roughly 5 years of treatment, patients with type 2 diabetes had a lower risk of MACE.
Conference Coverage
Immunotherapy drug teplizumab may stall onset of type 1 diabetes
The monoclonal antibody teplizumab may delay the onset of type 1 diabetes in individuals at high risk of developing the disease.
Conference Coverage
How to reverse type 2 diabetes with a crash diet: the DiRECT approach
SAN FRANCISCO – A few months of a medically supervised liquid diet; durable remission at 2 years.